Update shared on 17 Nov 2025
Fair value Increased 46%Analysts have raised their price target for GRAIL from $61.50 to $90.00. This change reflects increased confidence in the company’s long-term prospects and growth potential, following recent updates and a positive outlook on its multi-cancer early detection technology.
Analyst Commentary
Recent updates from street research show a notable shift among analysts regarding GRAIL's valuation and outlook. Following adjustments to company guidance and new data on its multi-cancer early detection (MCED) technology, both bullish and bearish perspectives have emerged.
Bullish Takeaways
- Bullish analysts are raising price targets significantly. This reflects greater confidence in GRAIL’s long-term growth, supported by promising updates on the Galleri test.
- Analysts highlight the company’s robust platform and clear path to capturing a larger share of the MCED market. This market is viewed as a substantial growth opportunity.
- Expectations for “substantially higher” positive predictive value in upcoming clinical studies, such as PATHFINDER 2, could further support future valuation increases.
- Potential changes to relevant legislation and advancements in product offerings may unlock additional commercial upside for GRAIL.
Bearish Takeaways
- Bearish analysts remain cautious about the execution risks inherent in developing and commercializing novel diagnostic technologies like Galleri.
- There are concerns about the sustainability of early momentum, particularly in light of competitive pressures and regulatory uncertainties in the MCED market.
- Questions persist regarding GRAIL’s ability to deliver consistent financial performance, as reliance on new and unproven technologies introduces volatility to growth projections.
- While recent data are encouraging, some analysts caution against over-optimism until additional clinical results and legislative developments are realized.
What's in the News
- Announced a $300 million follow-on equity offering for common stock at the market (Key Developments)
- Closed a private placement transaction with participation from 17 investors on November 7, 2025 (Key Developments)
- Positive performance and safety results from the PATHFINDER 2 study of the Galleri MCED test were presented at the ESMO Congress 2025, showing a substantially higher positive predictive value compared to previous studies (Key Developments)
- Released positive long-term results from the SYMPLIFY study, reinforcing the value of the Galleri test's cancer signal origin capability. Results were presented at the Early Detection of Cancer Conference (Key Developments)
- Signed a commercial lease agreement for a new 75,556-square-foot corporate headquarters in Sunnyvale, California (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has increased from $61.50 to $90.00, reflecting a notable upgrade in projected valuation.
- Discount Rate has edged up slightly from 6.94 percent to 7.00 percent. This indicates a minor adjustment in risk assessment.
- Revenue Growth Projection has risen from 19.6 percent to 23.5 percent, suggesting higher anticipated expansion in future sales.
- Net Profit Margin forecast has decreased modestly from 16.4 percent to 15.5 percent. This implies a slightly less favorable earnings outlook.
- Future P/E Ratio has increased from 87.9x to 125.5x, signaling higher expectations for earnings multiples going forward.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.